Dysport® (abobotulinumtoxinA) + Botox® (onabotulinumtoxinA)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cervical Dystonia
Conditions
Cervical Dystonia
Trial Timeline
Aug 1, 2009 → Jul 1, 2011
NCT ID
NCT00950664About Dysport® (abobotulinumtoxinA) + Botox® (onabotulinumtoxinA)
Dysport® (abobotulinumtoxinA) + Botox® (onabotulinumtoxinA) is a approved stage product being developed by Ipsen for Cervical Dystonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00950664. Target conditions include Cervical Dystonia.
What happened to similar drugs?
7 of 20 similar drugs in Cervical Dystonia were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00950664 | Approved | Completed |
Competing Products
20 competing products in Cervical Dystonia